Please login to the form below

Not currently logged in
Email:
Password:

major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

Alkermes slumps as FDA turns down depression drug

Alkermes slumps as FDA turns down depression drug

Despite a clinical efficacy and safety package with data from more than 30 clinical trials and around 1, 500 patients with major depressive disorder (MDD), the FDA has said it wants

Latest news

More from news
Approximately 6 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics